European Medicines Agency

#European Commission #European Medicines Agency #Minoryx Therapeutics #Neuraxpharm #Neurodegenerative disorders #Neuroscience

EC approves first treatment for rare neurodegenerative disease

The European Commission (EC) has granted marketing authorisation under exceptional circumstances for Nezglyal (leriglitazone), an orally bioavailable, brain penetrating, selective PPAR gamma agonist, as a treatment for male cALD patients.  It is approved in patients aged two to 12 years with Gadolinium (Gd)-negative brain lesions and is the first approved pharmacological… Read More

#Editor's Choice #News #Regulatory

Lungs
#Asthma #AstraZeneca #European Commission #European Medicines Agency

EC approves first triple-combination therapy for asthma maintenance

AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate or BGF) has been approved in the European Union (EU) as a maintenance treatment for asthma.  It is approved in patients 12 years of age and older who are not adequately controlled by a combination of a medium dose inhaled corticosteroid (ICS)… Read More

#News #Regulatory

The microbiome
#CHMP #European Medicines Agency #MaaT Pharma #Microbiome

CHMP raises concerns about microbiome therapy for GvHD

MaaT Pharma has received a negative trend vote from the Committee for Medicinal Products for Human Use (CHMP) for MaaT013 (Xervyteg) following re-examination for its conditional marketing authorisation application.  The committee’s concerns relate primarily to the attribution of clinical benefit and safety in the absence of a randomised control trial. … Read More

#News #Regulatory

Radiopharmaceutical drug
#European Medicines Agency #Oncology #Orphan drugs #Perspective Therapeutics #Radiopharmaceuticals

Perspective receives European orphan medicinal product designation

Radiopharmaceuticals company Perspective Therapeutics has received orphan medicinal product designation from the European Commission (EC) for [²¹²Pb]VMT-α-NET for the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).  The designation follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).  “Patients with unresectable or metastatic… Read More

#Cancer Research #News #Regulatory

Asthma inhaler
#Asthma #AstraZeneca #Committee for Medicinal Products for Human Use #European Medicines Agency

Asthma drug Trixeo recommended for approval in the EU

AstraZeneca’s fixed-dose triple-combination Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF) has been recommended for approval in the EU for the maintenance treatment of asthma in patients 12 years of age and older.  It is recommended in patients who are not adequately controlled by a combination of a medium dose inhaled corticosteroid… Read More

#News #Regulatory

The European Medicines Agency in Amsterdam
#European Medicines Agency #Minoryx Therapeutics #Neuraxpharm #Neurodegenerative disorders

Leriglitazone gets positive EU opinion for rare neurodegenerative disease

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional circumstances for Nezglyal (leriglitazone) as a treatment for male cALD patients, aged two to 12 years with gadolinium (Gd) negative brain lesions.   European Commission approval is expected by… Read More

#News #Regulatory

GSK offices
#European Medicines Agency #FDA #GSK #Orphan drugs #Rare disease

JAK inhibitor for VEXAS syndrome gets orphan drug designations

GSK’s momelotinib, a JAK inhibitor with a differentiated mechanism of action, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome.   VEXAS syndrome is a clonal myeloid disorder with… Read More

#News #Regulatory

Kidneys
#European Medicines Agency #Hansa Biopharma #Transplant

Hansa Biopharma and SERB enter €115m licensing agreement 

Hansa Biopharma and SERB have entered a licensing agreement worth €115 million for the development and commercialisation of a treatment for kidney transplant patients.  Idefirix (imlifidase) is a first-in-class treatment that targets and cleaves all classes of immunoglobulin G (IgG) antibodies within two to six hours. It is conditionally authorised by… Read More

#Business & Investment #News

The European Medicines Agency building
#CHMP #European Medicines Agency #Muscular dystrophy #Novartis

CHMP recommends gene replacement therapy for spinal muscular atrophy

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorisation for Novartis’ Itvisma (intrathecal onasemnogene abeparvovec).   The opinion supports its use for the treatment of children two years and older, teens, and adults living with 5q… Read More

#News #Regulatory

The European Medicines Agency in Amsterdam
#Drug discovery #European Medicines Agency #Regulatory

EMA launches tools to accelerate development of medicines

The European Medicines Agency (EMA) has launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines targeting an unmet medical need.   After the completion of a two-year pilot, the EMA has integrated these additional tools to support continued scientific dialogue, aiming to… Read More

#News #Regulatory

#Ascendis Pharma #BioIndustry Association #Cancer therapy #CHMP #Clinical trial #Diversity #European Medicines Agency #FDA #Gene therapy #Oncology #Paediatrics #Rare disease #uniQure #University of Queensland #Women in STEM

DDW Highlights: 10 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, figures showed the number of women in biotech leadership has stalled. Elsewhere, could… Read More

#Podcasts

The European Medicines Agency building
#CHMP #Clinical trial #European Medicines Agency

CHMP issues positive opinion on CSU targeted therapy 

The European Medicines Agency (EMA)’s Committee for Medicinal Products (CHMP) has adopted a positive opinion recommending marketing authorisation for a chronic spontaneous urticaria (CSU) treatment.  The opinion means remibrutinib, a highly selective oral BTKi developed by Novartis, could be the first targeted therapy approved for CSU in Europe.  The positive CHMP opinion is supported… Read More

#News #Regulatory

The European Medicines Agency building
#CHMP #European Medicines Agency #Oncology

CHMP recommends combination therapy to treat anal cancer  

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended Zynyz (retifanlimab) for the treatment of anal cancer.  Zynyz, developed by biopharmaceutical company Incyte, has received the EMA’s positive opinion to treat recurrent squamous cell carcinoma of the anal cancer (SCAC) in combination with… Read More

#Cancer Research #News

The European Medicines Agency in Amsterdam
#CHMP #European Commission #European Medicines Agency #Genetic diseases #Rare diseases #UCB

Kygevvi recommended in the EU for thymidine kinase 2 deficiency

UCB’s Kygevvi (doxecitine and doxribtimine) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation under exceptional circumstances.  The recommendation is for the treatment of paediatric and adult patients with genetically confirmed thymidine kinase 2 deficiency (TK2d)… Read More

#News #Regulatory

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

DDW Highlights: 27 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, an innovative therapy showed encouraging results in tackling melanoma. Elsewhere, why is… Read More

#Podcasts

#Canada #Cell and gene therapy #Clinical trial #Concussion #ELRIG #European Medicines Agency #Melanoma #Merck #Moderna #Oxeia Biopharmaceuticals #Regulatory #UK #Vaccines

This week in Drug Discovery (19 – 23 January) 

News round-up for 19 – 23 January by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies have shown encouraging results in tackling melanoma and concussion. Elsewhere, a UK-Canadian partnership looks to advance vaccine technology.  The top stories:    Combination therapy could slash melanoma mortality… Read More

#News